The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

“The initiation of our second clinical trial this year underscores our team’s productivity and execution, as well as the confidence that Scorpion and Pierre Fabre Laboratories have in the ...

Now it has a global partner for clinical development. France-based Pierre Fabre is paying Scorpion $65 million to begin an alliance on two Scorpion drug candidates. According to deal terms ...

In December 2023, Atara announced the closing of the expanded global partnership with Pierre Fabre Laboratories for the U.S. and remaining global commercial markets for tabelecleucel, building on ...

RedRidge will hold exclusive commercial rights in the United States, Canada, and Japan for both programs, while Pierre Fabre Laboratories will hold exclusive rest-of-world rights. In addition ...

CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ -- Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG ...

Then in 2023, Pierre Fabre took on the drug's U.S. rights in a deal worth up to $640 million. Related In deal worth up to $640M, Pierre Fabre doubles down on its T-cell partnership with Atara ...

Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody drug candidates against multiple targets, with a focus ...

Castres, France, July 25 th, 2024 – Pierre Fabre Laboratories announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of ...

CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 Financial terms of the agreement are not disclosed but include investment participation by Pierre Fabre ...

and Pierre Fabre Laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or EBVALLO™), today announced that data from the pivotal ...